Abstract
Purpose
Neuroendocrine prostate cancer (NEPC), a highly aggressive subtype of prostate cancer displaying resistance to hormone therapy, presents a poor prognosis and limited therapeutic options. Here, we aimed to find novel medication therapies for NEPC and explore the underlying mechanism.
Methods
A high-throughput drug screening utilizing an FDA-approved drug library was performed and ketotifen, an antihistamine agent, was identified as a potential therapeutic candidate for NEPC. The whole-transcriptome sequencing analysis was conducted to explore mechanism of ketotifen inhibitory in NEPC. Multiple cell biology and biochemistry experiments were performed to confirm the inhibitory effect of ketotifen in vitro. A spontaneous NEPC mice model (PBCre4:Ptenf/f;Trp53f/f;Rb1f/f) was used to reveal the inhibitory effect of ketotifen in vivo.
Results
Our in vitro experiments demonstrated that ketotifen effectively suppressed neuroendocrine differentiation, reduced cell viability, and reversed the lineage switch via targeting the IL-6/STAT3 pathway. Our in vivo results showed that ketotifen significantly prolonged overall survival and reduced the risk of distant metastases in NEPC mice model.
Conclusion
Our findings repurpose ketotifen for antitumor applications and endorse its clinical development for NEPC therapy, offering a novel and promising therapeutic strategy for this formidable cancer subtype.
Similar content being viewed by others
Data availability
All pertinent data and materials can be obtained from the corresponding author upon a reasonable request. The RNAseq data of LASCPC-01 cells treated with ketotifen or PBS was uploaded to the Gene Expression Omnibus database GSE225007.
Abbreviations
- NEPC:
-
Neuroendocrine prostate cancer
- FDA:
-
Food and Drug Administration
- IL-6:
-
Interleukin 6
- STAT3:
-
Signal transducer and activator of transcription 3
- JAK:
-
Janus Kinase
- AR:
-
Androgen receptor
- EMT:
-
Epithelial-mesenchymal transition
- PTEN:
-
Phosphatase and tensin homolog
- TP53:
-
Tumor protein 53
- RB1:
-
Retinoblastomal 1
- MYCN:
-
V-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
- AKT1:
-
AKT Serine/Threonine Kinase 1
- PBS:
-
Phosphate buffer saline
- IHC:
-
Immunohistochemistry
- H&E:
-
Hematoxylin-eosin
- p-:
-
Phosphorylated
References
W. Wang, J.I. Epstein, Am J Surg Pathol. 32(1), 65–71 (2008). https://doi.org/10.1097/PAS.0b013e318058a96b
Y. Wang, Y. Wang, X. Ci, S.Y.C. Choi, F. Crea, D. Lin, Y. Wang, Nature reviews. Urology 18, 581–596 (2021). https://doi.org/10.1038/s41585-021-00490-0
E.G. Bluemn, I.M. Coleman, J.M. Lucas, R.T. Coleman, S. Hernandez-Lopez, R. Tharakan, D. Bianchi-Frias, R.F. Dumpit, A. Kaipainen, A.N. Corella, Y.C. Yang, M.D. Nyquist, E. Mostaghel, A.C. Hsieh, X. Zhang, E. Corey, L.G. Brown, H.M. Nguyen, K. Pienta, M. Ittmann, M. Schweizer, L.D. True, D. Wise, P.S. Rennie, R.L. Vessella, C. Morrissey, P.S. Nelson, Cancer Cell 32, 474-489 e476 (2017). https://doi.org/10.1016/j.ccell.2017.09.003
V. Conteduca, C. Oromendia, K.W. Eng, R. Bareja, M. Sigouros, A. Molina, B.M. Faltas, A. Sboner, J.M. Mosquera, O. Elemento, D.M. Nanus, S.T. Tagawa, K.V. Ballman, H. Beltran, Eur. J. Cancer 121, 7–18 (2019). https://doi.org/10.1016/j.ejca.2019.08.011
H. Beltran, D.S. Rickman, K. Park, S.S. Chae, A. Sboner, T.Y. MacDonald, Y. Wang, K.L. Sheikh, S. Terry, S.T. Tagawa, R. Dhir, J.B. Nelson, A. de la Taille, Y. Allory, M.B. Gerstein, S. Perner, K.J. Pienta, A.M. Chinnaiyan, Y. Wang, C.C. Collins, M.E. Gleave, F. Demichelis, D.M. Nanus, M.A. Rubin, Cancer Discov. 1, 487–495 (2011). https://doi.org/10.1158/2159-8290.CD-11-0130
H.-L. Tan, A. Sood, H.A. Rahimi, W. Wang, N. Gupta, J. Hicks, S. Mosier, C.D. Gocke, J.I. Epstein, G.J. Netto, W. Liu, W.B. Isaacs, A.M. De Marzo, T.L. Lotan, Clin. Cancer Res. 20, 890–903 (2014). https://doi.org/10.1158/1078-0432.CCR-13-1982
M.D. Nyquist, A. Corella, I. Coleman, N. De Sarkar, A. Kaipainen, G. Ha, R. Gulati, L. Ang, P. Chatterjee, J. Lucas, C. Pritchard, G. Risbridger, J. Isaacs, B. Montgomery, C. Morrissey, E. Corey, P.S. Nelson, Cell Rep. 31, 107669 (2020). https://doi.org/10.1016/j.celrep.2020.107669
S.Y. Ku, S. Rosario, Y. Wang, P. Mu, M. Seshadri, Z.W. Goodrich, M.M. Goodrich, D.P. Labbe, E.C. Gomez, J. Wang, H.W. Long, B. Xu, M. Brown, M. Loda, C.L. Sawyers, L. Ellis, D.W. Goodrich, Science 355, 78–83 (2017). https://doi.org/10.1126/science.aah4199
S. Deng, C. Wang, Y. Wang, Y. Xu, X. Li, N.A. Johnson, A. Mukherji, U.G. Lo, L. Xu, J. Gonzalez, L.A. Metang, J. Ye, C.R. Tirado, K. Rodarte, Y. Zhou, Z. Xie, C. Arana, V. Annamalai, X. Liu, D.J. Vander Griend, D. Strand, J.T. Hsieh, B. Li, G. Raj, T. Wang, P. Mu, Nat. Cancer 3, 1071–1087 (2022). https://doi.org/10.1038/s43018-022-00431-9
A. Schroeder, A. Herrmann, G. Cherryholmes, C. Kowolik, R. Buettner, S. Pal, H. Yu, G. Muller-Newen, R. Jove, Cancer Res. 74, 1227–1237 (2014). https://doi.org/10.1158/0008-5472.CAN-13-0594
M. Rokavec, M.G. Oner, H. Li, R. Jackstadt, L. Jiang, D. Lodygin, M. Kaller, D. Horst, P.K. Ziegler, S. Schwitalla, J. Slotta-Huspenina, F.G. Bader, F.R. Greten, H. Hermeking, J. Clin. Invest. 124, 1853–1867 (2014). https://doi.org/10.1172/JCI73531
G. Canesin, V. Maggio, M. Palominos, A. Stiehm, H.R. Contreras, E.A. Castellon, J. Morote, R. Paciucci, N.J. Maitland, A. Bjartell, R. Hellsten, Sci. Rep. 10, 13958 (2020). https://doi.org/10.1038/s41598-020-70948-5
J. Luo, K. Wang, S. Yeh, Y. Sun, L. Liang, Y. Xiao, W. Xu, Y. Niu, L. Cheng, S.N. Maity, R. Jiang, C. Chang, Nat. Commun. 10, 2571 (2019). https://doi.org/10.1038/s41467-019-09784-9
A. Rojas, G. Liu, I. Coleman, P.S. Nelson, M. Zhang, R. Dash, P.B. Fisher, S.R. Plymate, J.D. Wu, Oncogene 30, 2345–2355 (2011). https://doi.org/10.1038/onc.2010.605
C. Enriquez, V. Cancila, R. Ferri, R. Sulsenti, I. Fischetti, M. Milani, P. Ostano, I. Gregnanin, M. Mello-Grand, E. Berrino, M. Bregni, G. Renne, C. Tripodo, M.P. Colombo, E. Jachetti, Cancer Res. (2021). https://doi.org/10.1158/0008-5472.CAN-21-0163
J.K. Lee, J.W. Phillips, B.A. Smith, J.W. Park, T. Stoyanova, E.F. McCaffrey, R. Baertsch, A. Sokolov, J.G. Meyerowitz, C. Mathis, D. Cheng, J.M. Stuart, K.M. Shokat, W.C. Gustafson, J. Huang, O.N. Witte, Cancer Cell 29, 536–547 (2016). https://doi.org/10.1016/j.ccell.2016.03.001
A. Davies, S. Nouruzi, D. Ganguli, T. Namekawa, D. Thaper, S. Linder, F. Karaoglanoglu, M.E. Omur, S. Kim, M. Kobelev, S. Kumar, O. Sivak, C. Bostock, J. Bishop, M. Hoogstraat, A. Talal, S. Stelloo, H. van der Poel, A.M. Bergman, M. Ahmed, L. Fazli, H. Huang, W. Tilley, D. Goodrich, F.Y. Feng, M. Gleave, H.H. He, F. Hach, W. Zwart, H. Beltran, L. Selth, A. Zoubeidi, Nat. Cell Biol. 23, 1023–1034 (2021). https://doi.org/10.1038/s41556-021-00743-5
S. Nouruzi, D. Ganguli, N. Tabrizian, M. Kobelev, O. Sivak, T. Namekawa, D. Thaper, S.C. Baca, M.L. Freedman, A. Aguda, A. Davies, A. Zoubeidi, Nat. Commun. 13, 2282 (2022). https://doi.org/10.1038/s41467-022-29963-5
P. Mu, Z. Zhang, M. Benelli, W.R. Karthaus, E. Hoover, C.C. Chen, J. Wongvipat, S.Y. Ku, D. Gao, Z. Cao, N. Shah, E.J. Adams, W. Abida, P.A. Watson, D. Prandi, C.H. Huang, E. de Stanchina, S.W. Lowe, L. Ellis, H. Beltran, M.A. Rubin, D.W. Goodrich, F. Demichelis, C.L. Sawyers, Science 355, 84–88 (2017). https://doi.org/10.1126/science.aah4307
A. Berger, N.J. Brady, R. Bareja, B. Robinson, V. Conteduca, M.A. Augello, L. Puca, A. Ahmed, E. Dardenne, X. Lu, I. Hwang, A.M. Bagadion, A. Sboner, O. Elemento, J. Paik, J. Yu, C.E. Barbieri, N. Dephoure, H. Beltran, D.S. Rickman, J. Clin. Invest. 130, 3924–3940 (2019). https://doi.org/10.1172/JCI127961
N. Spetsieris, M. Boukovala, G. Patsakis, I. Alafis and E. Efstathiou, Cancers (Basel). 12(12), 3792 (2020). https://doi.org/10.3390/cancers12123792
H. Beltran, C. Oromendia, D.C. Danila, B. Montgomery, C. Hoimes, R.Z. Szmulewitz, U. Vaishampayan, A.J. Armstrong, M. Stein, J. Pinski, J.M. Mosquera, V. Sailer, R. Bareja, A. Romanel, N. Gumpeni, A. Sboner, E. Dardenne, L. Puca, D. Prandi, M.A. Rubin, H.I. Scher, D.S. Rickman, F. Demichelis, D.M. Nanus, K.V. Ballman, S.T. Tagawa, Clin. Cancer Res 25, 43–51 (2019). https://doi.org/10.1158/1078-0432.CCR-18-1912
A.S. Mansfield, D.S. Hong, C.L. Hann, A.F. Farago, H. Beltran, S.N. Waqar, A.E. Hendifar, L.B. Anthony, M.H. Taylor, A.H. Bryce, S.T. Tagawa, K. Lewis, J. Niu, C.H. Chung, J.M. Cleary, M. Rossi, C. Ludwig, R. Valenzuela, Y. Luo, R. Aggarwal, N.P.J. Precis, Oncol 5, 74 (2021). https://doi.org/10.1038/s41698-021-00214-y
L.C. Brown, S. Halabi, J.A. Somarelli, M. Humeniuk, Y. Wu, T. Oyekunle, L. Howard, J. Huang, M. Anand, C. Davies, P. Patel, J. Staats, K.J. Weinhold, M.R. Harrison, T. Zhang, D.J. George, A.J. Armstrong, Prostate Cancer Prostatic. Dis. (2022). https://doi.org/10.1038/s41391-022-00524-7
J. Drost, W.R. Karthaus, D. Gao, E. Driehuis, C.L. Sawyers, Y. Chen, H. Clevers, Nat. Protoc. 11, 347–358 (2016). https://doi.org/10.1038/nprot.2016.006
E. Dardenne, H. Beltran, M. Benelli, K. Gayvert, A. Berger, L. Puca, J. Cyrta, A. Sboner, Z. Noorzad, T. MacDonald, C. Cheung, K.S. Yuen, D. Gao, Y. Chen, M. Eilers, J.M. Mosquera, B.D. Robinson, O. Elemento, M.A. Rubin, F. Demichelis, D.S. Rickman, Cancer Cell 30, 563–577 (2016). https://doi.org/10.1016/j.ccell.2016.09.005
H. Guo, X. Ci, M. Ahmed, J.T. Hua, F. Soares, D. Lin, L. Puca, A. Vosoughi, H. Xue, E. Li, P. Su, S. Chen, T. Nguyen, Y. Liang, Y. Zhang, X. Xu, J. Xu, A.V. Sheahan, W. Ba-Alawi, S. Zhang, O. Mahamud, R.N. Vellanki, M. Gleave, R.G. Bristow, B. Haibe-Kains, J.T. Poirier, C.M. Rudin, M.S. Tsao, B.G. Wouters, L. Fazli, F.Y. Feng, L. Ellis, T. van der Kwast, A. Berlin, M. Koritzinsky, P.C. Boutros, A. Zoubeidi, H. Beltran, Y. Wang, H.H. He, Nat. Commun. 10, 278 (2019). https://doi.org/10.1038/s41467-018-08133-6
P. Mu, Z.D. Zhang, M. Benelli, W.R. Karthaus, E. Hoover, C.C. Chen, J. Wongvipat, S.Y. Ku, D. Gao, Z. Cao, N. Shah, E.J. Adams, W. Abida, P.A. Watson, D. Prandi, C.H. Huang, E. de Stanchina, S.W. Lowe, L. Ellis, H. Beltran, M.A. Rubin, D.W. Goodrich, F. Demichelis, C.L. Sawyers, Science 355, 84–88 (2017). https://doi.org/10.1126/science.aah4307
A. Davies, S. Nouruzi, D. Ganguli, T. Namekawa, D. Thaper, S. Linder, F. Karaoğlanoğlu, M.E. Omur, S. Kim, M. Kobelev, S. Kumar, O. Sivak, C. Bostock, J. Bishop, M. Hoogstraat, A. Talal, S. Stelloo, H. Van Der Poel, A.M. Bergman, M. Ahmed, L. Fazli, H. Huang, W. Tilley, D. Goodrich, F.Y. Feng, M. Gleave, H.H. He, F. Hach, W. Zwart, H. Beltran, L. Selth, A. Zoubeidi, Nature Cell Biol. 23, 1023–1034 (2021). https://doi.org/10.1038/s41556-021-00743-5
C. Bimbi, V.M. Riccardi, D. Koumoundourou, G. Kyriakou, Dermatol. Ther. 33, e13670 (2020). https://doi.org/10.1111/dth.13670
F.M. Khan, E. Saleh, H. Alawadhi, R. Harati, W.-H. Zimmermann, R. El-Awady, Cancer Biol. Ther. 19, 25–33 (2018). https://doi.org/10.1080/15384047.2017.1394544
M. Groeger, G. Spanier, M. Wolf, J. Deschner, P. Proff, A. Schroder, C. Kirschneck, Plos One 15, e0237040 (2020). https://doi.org/10.1371/journal.pone.0237040
C.L. Lee, S.H. Hsu, Y.J. Jong, C.H. Hung, J.L. Suen, Int. Arch. Allergy Immunol. 160, 265–274 (2013). https://doi.org/10.1159/000341637
N.A. El-Shitany, K. El-Desoky, Drug Des. Devel. Ther. 9, 5237–5246 (2015). https://doi.org/10.2147/DDDT.S88337
Z. Chen, H. Sun, J. Wang, L. Ni, X. Gu, S. Ge, Q. Chen, L. Mu, X. Cheng, Endocr. J. 64, 411–416 (2017). https://doi.org/10.1507/endocrj.EJ16-0458
Funding
The work was supported by National Natural Science Foundation of China (No 82072847, 81772742, 82172868, 81972578), Ren Ji Hospital (PYI20-04, LYZXHXKT220845, 2020LYRJ-002, PNO-0106, RJKY18-02). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.
Author information
Authors and Affiliations
Contributions
QW, and WX contributed to conception and design of the study. YJ, BL, and LC organized the database. YJ, RS, and KS performed the statistical analysis. YJ, BL, and LC wrote the first draft of the manuscript. AL and WZ wrote sections of the manuscript. QW, YZ, and WX obtained the funding. All authors contributed to manuscript revision, read, and approved the submitted version.
Corresponding authors
Ethics declarations
Ethics approval
All mice experimental procedures were approved by the Research Ethics Committee of Ren Ji Hospital. The research was conducted in accordance with the Ethical Principles of Measures for Ethical Review of Biomedical Research Involving Human Beings and the Declaration of Helsinki.
Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ji, Y., Liu, B., Chen, L. et al. Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway. Cell Oncol. 46, 1445–1456 (2023). https://doi.org/10.1007/s13402-023-00822-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13402-023-00822-9